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Background: Asthma is a chronic inflammatory airway disease in which innate and adaptive immune 
cells act together to cause eosinophilic inflammation, goblet cell metaplasia (GCM) and bronchial 
hyperreactivity (BHR). In clinical trials employing biologicals against interleukin (IL)-4Rα or IL-5, only 
a subset of moderate-to-severe asthmatics responded favorably, suggesting that distinct 
pathophysiological mechanisms are at play in subgroups of patients, called endotypes. However, the 
effect of multiple cytokine blockade using bispecific antibodies (Ab) has not been tested.  
Objective: To target simultaneously IL-4, IL-13 and IL-5 signaling pathways with a novel IL-4Rα/IL-
5 bispecific Ab in a murine house dust mite (HDM) model of asthma. 
Methods: Two monoclonal Abs neutralizing IL-4Rα and IL-5 were generated using a llama-based Ab 
platform. Their heavy (HC) and light chains (LC) where then co-transfected in mammalian cells, 
resulting in a heterogeneous Ab mixture from which the bispecific Ab was isolated using a dual anti-
idiotypic purification process. C57BL/6J mice were finally sensitized and challenged to HDM extracts 
and treated during challenge with the Abs. 
Results: We successfully generated and characterized the monospecific and bispecific Abs targeting IL-
4Rα and IL-5. The monospecific Abs could suppress eosinophilia and/or IgE synthesis whereas only the 
IL-4Rα/IL-5 bispecific Ab and the combination of monospecific Abs additionally inhibited GCM and 
BHR. 
Conclusion: Type 2 cytokines act synergistically to cause GCM and BHR in HDM-exposed mice. 
Clinical applications: These preclinical results show the feasibility of generating bispecific Abs that 
target multiple cytokine signaling pathways as superior inhibitors of asthma features, including the 
difficult-to-treat GCM. 
 
Clinical implications: This preclinical study demonstrates the feasibility of developing a bispecific Ab 
targeting multiple cytokine pathways as a potent inhibitor of asthma features, including the difficult-to-
treat GCM, providing a new therapeutic approach to treat patients with moderate-to-severe asthma or 
with other chronic airway diseases in which mucus overproduction is often seen. 
 
Capsule summary: Current asthma biologicals include IL-4Rα and IL-5 monospecific Abs. Here we 
show the feasibility of producing an anti-IL-4Rα/IL-5 bispecific Ab that neutralizes both targets and 
demonstrates superior effectiveness in a murine house dust mite model.  
 
Key words: asthma, bispecific antibody, bronchial hyperreactivity, goblet cell metaplasia, house dust 
mite, interleukin-4 receptor alpha, interleukin-5 
 
Abbreviations used 
Ab: Antibody  
BAL: Bronchoalveolar lavage 
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BHR: Bronchial hyperreactivity 
ELISA: Enzyme-linked immunosorbent assay 
Fab: Antigen-binding fragment 
FACS: Fluorescence-activated cell sorting 
Fc: Fragment crystallizable 
GCM: Goblet cell metaplasia 
HC: Heavy chain 
HDM: House dust mite 
ICS: Inhaled corticosteroid 
Ig: Immunoglobulin 
IL: Interleukin 
LABA: Long-acting β2-adrenergic agonist 
LC: Light chain 
MHC: Major histocompatibility complex 
MLN: Mediastinal lymph node 
Muc5AC: Mucin 5AC 
PBS: Phosphate-buffered saline 
qRT-PCR: Quantitative reverse transcription polymerase chain reaction 
SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM: Standard error of the mean 
SPDEF: Sam-pointed domain containing Ets transcription factor 
SPR: Surface plasmon resonance 


















Asthma is a chronic inflammatory disease of the conducting airways affecting up to 300 million 
people worldwide that leads to symptoms of coughing, wheezing and chest tightness.1-4 Airway 
obstruction runs a variable course, with symptom-free periods interrupted by periods of exacerbations, 
often caused by viral infection.2 A typical feature is BHR, which is the tendency of the airways to 
constrict in response to stimuli such as cold air and exercise. Allergic sensitization to inhaled allergens 
such as HDMs (Dermatophagoides pteronyssinus), which concerns about 50% of asthmatic patients,5 is 
often found in children with asthma and characterized by the presence of allergen-specific 
immunoglobulin (Ig) E in serum (so-called atopic predisposition). Only half of adults with asthma are 
atopic, but the disease otherwise presents similarly in the clinic.6 
In bronchial biopsies or lung-resection samples, asthma is often characterized by accumulation 
of eosinophils, mast cells and CD4+ T lymphocytes producing the type 2 cytokines IL-4 and/or IL-5 in 
the epithelium and lamina propria, even in individuals who have non-atopic asthma.7-9 Animal models 
in which CD4+ T cells or type 2 cytokines such as IL-4, IL-5 or IL-13 have been individually knocked 
out, have provided important evidence that the type 2 axis can drive eosinophilic airway inflammation 
and BHR.10 However, asthma in humans is heterogeneous and a type 2-biased response disease seems 
to be detectable in only 50% of individuals with asthma, particularly those with early onset disease, an 
atopic predisposition and high blood eosinophil counts.11 In some individuals with asthma, particularly 
those who respond poorly to steroids, airway infiltrates are composed primarily of neutrophils, which 
are probably recruited to the airways by IL-17-producing cells such as T-helper type 17 lymphocytes or 
γδT cells.6, 12 
The finding of distinct clinical subsets of asthma that are driven by distinct pathophysiological 
mechanisms is also reflected in clinical trials employing biologicals aimed at blocking type 2 cytokines, 
wherein drugs targeting specifically IL-4Rα (e.g. dupilumab, targeting both IL-4 and IL-13 signaling 
pathways), IL-5 (e.g. mepolizumab or reslizumab) or IL-5Rα (benralizumab), are only effective for a 
subset of severe asthmatics that can be identified through the use of biomarkers.13 Despite these 
differences in the clinical presentation, therapeutic responsiveness and underlying etiology of disease 
(called endotypes), there are signs of airway remodeling in almost all forms of asthma. These changes 
consist of an increase in the smooth-muscle mass surrounding the airway wall, a deposition of 
extracellular matrix components under the epithelial basement membrane that causes a thickened 
appearance, a breach in the integrity of the airway epithelium and an increase of mucus-producing goblet 
cells in the epithelium or submucosal glands.14  
The increase in goblet cells and increased mucus production, is not due to the proliferation of 
pre-existing goblet cells but rather to the transdifferentiation of ciliated and secretory cells to goblet 
cells, under the influence of IL-4 and/or IL-13 and ligands of the epidermal growth factor receptor, and 
is therefore termed GCM.14, 15 Goblet cells produce mucins, such as Mucin 5AC (Muc5AC), which 
control the viscoelasticity and hydration of the mucus covering the ciliary escalator.14, 16 In asthma, the 
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sputum is often so dry that it can lead to mucus impaction and severe airway obstruction, and currently 
few therapeutic options exist to reduce GCM and improve mucus clearance.16  
The types of patients that react best to currently (or soon to be) available biologicals all fall 
within the so-called type 2 asthma endotype, characterized by high blood and sputum eosinophilia and/or 
elevated allergen-specific serum IgE levels.13 Many studies show that IgE synthesis, airway 
inflammation, remodelling and BHR are dissociated and may be mediated by different mechanisms 
under different conditions.17 Yet, to date combination therapies targeting collaboratively inflammatory 
and potentiating pathways in asthma, such as an anti-IL-4Rα/IL-5 drug targeting simultaneously the IL-
4, IL-13 and IL-5 pathways, have not been investigated. 
Here, we generated and characterized novel conventional monospecific Abs directed against IL-
4Rα and IL-5 using a llama-based Ab platform, which sources human-like V-regions from the immune 
system of "outbred" llamas (i.e. that each animal has a different genetic background, Fig E1, A). The 
outbred nature and the low degree of sequence homology between the human or mouse and the llama 
proteins explain why each llama is able to generate a unique but very diverse individual immune 
response, providing a wide array of Ab V-regions against the immunogens.18 We then used the most 
neutralizing monospecific Abs to generate the anti-IL-4Rα/IL-5 bispecific Ab and purified it using a 
dual anti-idiotypic purification process (Fig E2, A). Using these Abs, we showed a novel synergistic 
effect of simultaneously targeting IL-4, IL-13 and IL-5 signaling pathways during challenge of a murine 
HDM model of asthma, with a potent capacity to reduce eosinophilic lung inflammation and allergen-
specific IgE synthesis, prevent GCM and inhibit BHR in response to HDM challenge. This preclinical 
study demonstrates the feasibility of developing a bispecific Ab targeting multiple cytokine pathways 
as a potent inhibitor of asthma features, including the difficult-to-treat GCM, providing a new 
therapeutic approach to treat patients with moderate-to-severe asthma or with other chronic airway 

















Llama immunization and library construction 
Two llamas, farmed outdoors according to the French animal welfare legislation, were 
immunized intramuscularly once per week over six weeks with recombinant mouse IL-4Rα-Fc and IL-
5 (R&D Systems). They received 100 μg of IL-4Rα-Fc and 50 µg of IL-5, buffered in phosphate-
buffered saline (PBS) and mixed with Incomplete Freund’s Adjuvant (Sigma-Aldrich), the first two 
weeks, and 50 μg of IL-4Rα-Fc and 25 µg of IL-5 the remaining four weeks. Generation of Ab libraries 
was performed using the proprietary SIMPLE antibodyTM platform at argenx as previously described 
(Fig E1, A).19 Briefly, five days after the last immunization, peripheral blood lymphocytes were purified 
and used for extraction of total RNA. Total RNA was then converted into random primed cDNA using 
reverse transcriptase, and gene sequences encoding for VH-CH1 regions of llama IgG and VL-CL 
domains (kappa and lambda) were isolated and subcloned into a phagemid vector pCB3. 
Phage selection for Fab generation 
The E. coli strain TG1 (Netherlands Culture Collection of Bacteria) was transformed using 
recombinant phagemids to generate antigen-binding fragments (Fab)-expressing phage libraries (one 
lambda and one kappa library per immunized llama). Because the llamas were immunized with IL-4Rα 
fused to a fragment crystallizable (Fc) part, a counter-selection against an excess of Fc in solution was 
performed to get rid of phages expressing Fabs directed against Fc. The phages were adsorbed on 
immobilized recombinant biotinylated IL-4Rα-Fc or IL-5, and eluted using trypsin as previously 
described.20 Three rounds of phage display selections were performed to enrich for phages expressing 
IL-4Rα or IL-5-specific Fabs. TG1 E. coli was finally infected with selected phages, and individual 
colonies were isolated. Secretion of Fabs was induced using isopropyl β-D-1-thiogalactopyranoside 
(Sigma-Aldrich), and the Fab-containing periplasmic fractions of bacteria were collected and screened 
by surface plasmon resonance (SPR) using a Biacore 3000 apparatus (GE Healthcare).  
Monospecific Ab production, purification and characterization 
The cDNAs encoding the VH and VL (lambda or kappa) domains of the neutralizing Fabs 
fragments displaying the lowest off-rate were cloned into two separate mammalian expression vectors 
(U-Protein Express BV) which comprise the cDNAs encoding the CH1, hinge, CH2 and CH3 domains 
of a mouse IgG2a Ab, containing a mutation that abrogates Ab effector functions mediated by the Fc 
receptor (e.g. N297A)21, or the CL (lambda or kappa), respectively. Production by transient transfection 
of HEK293 cells and endotoxin-free purification by protein A affinity chromatography was then 
performed to generate mouse IgG2a monoclonal Abs containing the N297A mutation. Their purity and 
homogeneity were verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE, 
2 μg of each sample, Fig E1, B), and their high affinity (8E-11 M for the anti-IL-4Rα monospecific Ab 
depicted in Fig E1, C and 2E-12M for the anti-IL-5 monospecific Ab depicted in Fig E1, D) and ability 
to neutralize their target (Fig E1, E) were determined by SPR. The neutralizing activity of both anti-IL-
4Rα and anti-IL-5 monospecific Abs was finally confirmed in in vitro cellular assays, in which mouse 
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IL-4 and IL-5 induced the proliferation of HT-2 and TF-1 cells, respectively. Anti-IL-4Rα and anti-IL-
5 monospecific Abs blocked the cellular proliferation induced by mouse IL-4 and IL-5 with an EC50 
equals to 0.2 nM and 0.6 nM, respectively (Fig E1, F). Additionally, the ability of the anti-IL-4Rα 
monospecific Ab to block the translocation of MHC class II to the surface of B cells induced by mouse 
IL-4 was tested as previously described (Fig E1, G).22 
Cell proliferation assays 
Human TF-1 cells (erythroblasts, ATCC CRL-2003) and mouse HT-2 clone A5E cells (IL-2 
dependent T lymphocytes, ATCC CRL-1841) were cultured at 37°C with 5% (v/v) CO2 in growth 
medium containing RPMI 1640 (Sigma), 10 % (v/v) heat-inactivated fetal bovine serum (Sigma), 
1X gentamycin (Sigma), and 2 ng/mL human granulocyte-macrophage colony-stimulating factor (R&D 
Systems) or human IL-2 (R&D Systems), respectively. These cytokines were replaced in the assay 
medium by mouse IL-5 for the TF-1 cells and mouse IL-4 for the HT-2 cells (0.25 ng/mL and 7.5 ng/mL, 
respectively, R&D Systems) and added to a serial titration of the Abs. Cells were washed and 
resuspended at a final cell density of 1.1 × 106 cells/mL for the TF-1 cells or 0.2 × 106 cells/mL for the 
HT-2 cells. Cells were then added to the assay medium before addition of the CellTiter 96 AQueous One 
Solution Reagent (Promega). After 3h of incubation, the absorbance was measured (Fig E1, F and G). 
Generation of anti-idiotypic VHH affinity purification columns 
A phage display library encoding the variable domain of camelid single-domain Ab fragments 
(VHH) from naïve llama was generated as described.23 VHHs specific of each idiotype formed by the 
properly paired VH and VL were selected by phage display as previously described.24-26 One potent anti-
idiotypic VHH for each monospecific Ab was produced, purified and coupled to 5 mL NHS-sepharose 
beads according to the manufacturer’s protocol (GE Healthcare). The VHH-functionalized sepharose 
beads were packed into small Tricorn columns (GE Healthcare). Analysis of the specificity of the 
columns was studied by chromatography experiments (AKTA prime, GE Healthcare) as previously 
described.26 
Bispecific Ab production and purification using a dual anti-idiotypic purification process 
The bispecific Ab was produced in HEK293 cells by co-transfecting 1:1:1:1 of the HCs and LCs 
of the two parental monospecific Abs containing the knobs-into-holes mutations to force HC 
heterodimerization through a symmetric-to-asymmetric complementarity design (Fig E2, A).27, 28 After 
protein A purification, the Ab mixture was injected onto the VHH anti-IL-4Rα monospecific Ab-
functionalized column followed by the injection of the eluted fraction into the VHH anti-IL-5 
monospecific Ab-functionalized column. Abs were eluted with 20 mM citrate buffer, 150 mM sodium 
chloride pH3.0 and subsequently neutralized with 1M potassium phosphate pH 8.0 (1/10 of the eluted 
volume). Finally, the bispecific Ab was concentrated, buffer exchanged to PBS (0.02% v/v)-Tween-80 
and filter sterilized. The purity of the eluted bispecific Ab was tested by high-resolution mass 
spectrometry (Fig E2, B, 5 μg of each sample, RIC BVBA, Kortrijk, Belgium), whereas its binding 
ability was confirmed by SPR as previously described (Fig E2, C and D).26 
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HDM mouse model  
Experiments were approved by the ethical committee of the VIB-UGent Center for 
Inflammation Research. Female C57BL/6J wild-type mice were obtained from Jackson. All mice were 
used between 6-8 weeks of age. Experiments were carried out using age-matched groups. On day 0, 
mice were lightly anesthetized with isofluorane (2.5% v/v in air) and received 1 μg HDM (Greer 
Laboratories) intratracheally. On days 6-10, mice were lightly anesthetized with isofluorane (2.5% v/v 
in air) and challenged daily with 10 μg HDM intranasally. On days 6, 8 and 10, mice received 
intraperitoneally their Ab treatment 4h before challenge. As controls, mice were sensitized with HDM, 
challenged with PBS and treated with an irrelevant IgG2a Ab, or sensitized and challenged with HDM 
and treated with an irrelevant IgG2a Ab. 
Collection and analysis of sera, BAL fluid, MLN cells and lungs 
On day 14, mice were euthanized. Bronchoalveolar lavage (BAL) was performed using 3 × 1 
mL of EDTA-containing PBS into the cannulated trachea, and the cellular composition was determined 
by fluorescence-activated cell sorting (FACS) as previously described.29-31 Blood was obtained from the 
iliac vein, the serum was subsequently prepared and the quantities of HDM-specific IgE and IgG1 were 
determined as previously described.31 Single cell suspensions (2 × 106 cells/mL) were obtained from 
mediastinal lymph nodes (MLN) by homogenizing the organ through a 100 μm cell sieve. Cells were 
restimulated ex vivo with 15 μg/mL HDM for 3 days in 96 round-bottom plates and supernatants were 
collected to determine the cytokine production by using the Read-SET-Go! Enzyme-linked 
immunosorbent assay sets (ELISA, eBioscience). Lungs were injected with PBS/OCT (1:1) solution, 
snap-frozen in liquid nitrogen and kept at -80°C until further processing for Muc5AC 
immunofluorescence staining as previously described.29 Alternatively, lungs were snap-frozen in liquid 
nitrogen and kept at -80°C until further processing for real-time quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) as previously described.30 Briefly, RNA was obtained by using 
the TriPure Isolation Reagent (Roche) and isolated according to the manufacturer’s instructions. RNA 
was reverse transcribed with a Transcriptor High Fidelity cDNA Synthesis Kit (Roche), and samples 
were analyzed by using SYBR green-based qRT-PCR with a LightCycler 480 system (Roche) against 
reference genes (Rpl13a, Hprt and Sdha). Otherwise, lung function was performed using an invasive 
measurement of dynamic resistance (Flexivent, Scireq) as previously described.31 
Statistical analysis 
Data are represented as means ± standard error of the means (SEM). Statistical significances 
between groups were calculated using the one-way ANOVA test with GraphPad Prism software v7.01 
and Genstat software v19. Differences between groups were considered significant when *P≤0.05, 
**P≤0.01, ***P≤0.001 and ****P≤0.0001, versus the group of mice sensitized and challenged with 






Combination of anti-IL-4Rα and anti-IL-5 monospecific Abs injected during challenge inhibited 
GCM and BHR 
HDM is an important human allergen, which induces allergic airway inflammation in sensitized 
and challenged mice, in a model resembling human type 2-high allergic asthma.30-32 Mice were subjected 
to the HDM sensitization and challenge protocol and received the monotherapy (high affinity and 
neutralizing anti-IL-4Rα or anti-IL-5 conventional monospecific Abs, newly generated using a llama-
based platform as described in the Methods section and Fig E1), or a combination of both monotherapies 
during the entire sensitization and challenge period (Fig E3, A). As previously reported in this model, 
airway HDM exposure increased the total count of inflammatory cells (mainly lymphocytes and 
eosinophils) in BAL fluid of mice as observed in the mice treated with an irrelevant IgG2a Ab 
(Fig E3, B).30-32 The numbers of BAL fluid lymphocytes and eosinophils were significantly decreased 
by the monotherapies as well as the combination of both monotherapies. Blocking IL-4Rα resulted in 
an improved efficacy as found for the IL-4Rα monotherapy and the combination of both monotherapies, 
which can be explained by the fact that IL-4 is needed to cause T-helper type 2 sensitization to inhaled 
antigen.33  
To further study the effect of the combination therapy, the Ab treatments were given only during 
challenge as depicted in Fig 1, A. Based on previous titration experiments, a treatment dose of 150 µg 
per monospecific Ab was chosen (data not shown). Airway HDM exposures increased the total count of 
inflammatory cells (mainly lymphocytes and eosinophils) in BAL fluid compared to PBS-challenged 
mice (Fig 1, B; HDM-sensitized and -challenged mice treated with an irrelevant IgG2b Ab represented 
by the black bars, compared to the white bars representing HDM-sensitized/PBS-challenged mice 
treated with an irrelevant IgG2a Ab). The numbers of lymphocytes and eosinophils were significantly 
decreased after treatment with the monotherapies as well as the combination therapy. However, the 
lowest numbers of lymphocytes and eosinophils were seen in mice treated with the combination therapy, 
suggesting a possible synergistic effect of targeting IL-4Rα and IL-5. 
Key aspects of airway inflammation are driven by the effector cytokines IL-5 and IL-13 
produced by allergen-specific type 2 cells in the lungs and lymphoid organs.34 The in vitro production 
of these cytokines was boosted in allergen-restimulated cultures of MLN cells isolated from IgG2a Ab-
treated, HDM-sensitized and -challenged mice (Fig 1, C). This response was significantly decreased 
after in vivo treatment with the anti-IL-4Rα monospecific Ab and combination of both monotherapies 
whereas anti-IL-5 monospecific Ab had no significant effects. Similarly, the serum concentration of IL-
4 dependent HDM-specific IgG1 and IgE was boosted by allergen challenge in IgG2a Ab treated mice 
and significantly reduced in mice treated with the anti-IL-4Rα monospecific Ab and combination of 
both monotherapies, but not (HDM-specific IgE) or less significantly (HDM-specific IgG1) affected by 
the anti-IL-5 monospecific Ab treatment (Fig 1, D). 
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GCM is driven by IL-13 and characterized by increased production of Muc5AC, a gel-forming 
mucin present in the airways of asthmatic mice and humans.35 In irrelevant IgG2a Ab treated and HDM-
sensitized mice, HDM challenge caused increased immunoreactivity for Muc5AC in the airway 
epithelium, compared with PBS challenge, as shown in Fig 1, E. The increased staining for Muc5AC 
was not affected by IL-4Rα or IL-5 monotherapies. Strikingly however, lungs from mice treated with 
the combination of monospecific Abs had strongly reduced staining intensity for Muc5AC compared to 
the other HDM-sensitized and -challenged groups. To confirm and quantify the effects of the 
combination of both monotherapies on GCM, the mRNA expression level of Muc5ac, as well as two 
other genes involved in GCM, Agr2 and Spdef, were measured by qRT-PCR in lung tissues. Sam-pointed 
domain containing Ets transcription factor (SPDEF) regulates various genes that encode factors involved 
in producing mucins, their glycosylation, and intracellular packaging, including Muc5ac and Agr2.36, 37 
The mRNA expression levels of these three genes were induced by HDM challenge in mice compared 
to PBS challenge (Fig 1, F). The IL-4Rα monotherapy was not able to reduce the mRNA expression 
levels of these three genes whereas the IL-5 monotherapy reduced the expression of Spdef. Strikingly, 
the combination of both monotherapies strongly reduced the mRNA expression levels of the three genes 
(Fig 1, F), confirming the observation made at protein level for Muc5AC (Fig 1, E) and suggesting that 
the combination therapy acted downstream of phosphorylated STAT6 to inhibit IL-13/STAT6 signaling 
in airway epithelium. 
BHR is the tendency of the airways to constrict in response to low amounts of 
bronchoconstrictor agents like the muscarinic receptor agonist methacholine. In irrelevant IgG2a Ab 
treated mice, HDM-challenged and -sensitized mice, methacholine caused increased airway resistance 
compared to PBS-challenged and HDM-sensitized mice (Fig 1, G). Treatment with the monotherapies 
did not reduce BHR, but strikingly, mice treated with the combination of both monotherapies were 
completely protected from developing BHR, showing an unexpected synergistic effect of the 
monotherapies when injected in combination. 
Altogether, these results showed that the combination of IL-5 and IL-4Rα monospecific Abs 
given during challenge in HDM-exposed mice had unforeseen synergistic effects on key aspects of 
asthma, including GCM and BHR. 
 
Anti-IL-4Rα/IL-5 bispecific Ab treatment injected during challenge inhibited GCM and BHR 
During the past decade, dual targeting with bispecific Abs has emerged as an alternative to 
combination therapy. From a practical, technological, intellectual property and regulatory perspective, 
this makes the development less complex because manufacturing, preclinical and clinical testing, and 
administration is reduced to a single molecule.38 Therefore, we generated an anti-IL-4Rα/IL-5 bispecific 
Ab using a dual anti-idiotypic purification process (Fig E2, A).26  
We then tested the in vivo activity of the bispecific Ab and compared it with the monotherapies 
(anti-IL-4Rα or anti-IL-5 monospecific Abs) and the combination of both monotherapies. To conserve 
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equimolar inhibition of targets, and to eliminate differences in the total amount of Ab, we compared the 
effect of dosing 75 µg of each monospecific Ab combined with 75 µg of an irrelevant IgG2a Ab, a 
combination of 75 µg of each monospecific Abs and 150 µg of the bispecific Ab. 
Mice were subjected as previously to the HDM sensitization and challenge protocol and treated 
with the Abs during challenge (Fig 1, A). Even with this lower treatment dose compared to the 
experiments showed in Fig 1, the numbers of eosinophils induced by HDM challenge in sensitized mice 
were significantly decreased after the injections of the monospecific Abs as well as the combination of 
both monotherapies (Fig 2, A). However, the lowest numbers of eosinophils, as well as lymphocytes, 
were seen in mice treated with the combination therapy, suggesting a possible synergistic effect of 
targeting IL-4Rα and IL-5 as previously observed (Fig 1, B). Notably, the bispecific Ab was as effective 
as the combination of both monotherapies in reducing airway eosinophilia and lymphocytosis induced 
by allergen challenge. The in vitro MLN type 2 cytokine (IL-5 and IL-13) production (Fig 2, B) as well 
as HDM-specific IgE and IgG1 (Fig 2, C) were also significantly decreased after treatment with either 
the combination of both monotherapies or the bispecific Ab. 
To test and to compare the effects of the bispecific Ab on GCM, the mRNA expression levels 
of Muc5ac, Spdef and Agr2 were measured in lung tissue. Interestingly, their expressions were reduced 
by either the combination of both monotherapies or the bispecific Ab, but not by the monotherapies 
(Fig 2, D). Only expression of Spdef was reduced by the IL-5 monotherapy whereas the IL-4Rα 
monotherapy was not able to reduce mRNA expression level of these three genes as previously shown 
in Fig 1, F. More remarkably, treatment with either the combination of both monotherapies or the 
bispecific Ab protected lungs equally well from HDM induced BHR, as assessed by methacholine 
induced bronchoconstriction (Fig 2, E).  
Altogether these results showed that a bispecific Ab targeting simultaneously IL-4, IL-13 and 
IL-5 signaling pathways is effective in reducing all salient asthma features when given during challenge 
















Since the early 1990’s, it has become clear that asthma is frequently a type 2 mediated disorder, 
often occurring in patients with atopic predisposition, and characterized by the presence of airway and 
blood eosinophils, GCM, airway remodeling and BHR that leads to frequent exacerbations.2, 7, 8, 39 In 
many patients, the disease can be controlled by a combination of nonspecific drugs, an inhaled 
corticosteroid (ICS) and a short- or long-acting β2-adrenergic agonist (LABA). Nevertheless, in 5 to 
10% of asthmatics, called severe asthmatics, the disease runs a severe course, requiring a need for new 
and more effective drugs to prevent the occurrence of potentially life-threatening episodes. 
Despite the initial setbacks targeting type 2 cytokines in asthma, the therapeutic potential and 
proven benefit of targeting individual type 2 mediators (such as IgE, IL-5, IL-5Rα and IL-4Rα) has now 
been established in endotypes of asthmatics who match the therapeutic mechanism. Indeed, the 
therapeutic monospecific Ab targeting IL-4Rα (dupilumab) was shown to reduce asthma exacerbation 
frequency and IgE levels, and improved lung function after ICS and LABA withdrawal in patients with 
persistent moderate-to-severe asthma and elevated blood or sputum eosinophil counts. In these patients, 
dupilumab treatment had no effect on the elevated eosinophil counts however, and in four patients 
eosinophil levels even went up after a 12-week therapy period.40 Abs targeting IL-5 (e.g. mepolizumab 
or reslizumab) or IL-5Rα (benralizumab) have also been extensively tested and can now be used as add-
on therapy to ICS and LABA in patients with persistent moderate-to-severe asthma and high blood 
eosinophil counts, to reduce exacerbation frequency and ICS use.41-47 
In the studies targeting IL-4Rα, IL-5 or IL-5Rα, all patients were selected as having a type 2 
signature, characterized by blood and/or tissue eosinophilia and often accompanied by high serum IgE 
levels. Although these therapies have shown benefit in the entire study population, it is possible that 
some patients in which one therapy is not so effective or even in those where it is effective, there might 
be greater benefit from blocking additional type 2 cytokines. This is certainly reflected in the dupilumab 
clinical trial studies, where treatment did not reduce blood eosinophilia.40 It is indeed known that the 
cytokine pathways can be very redundant.48 Combining two monoclonal Abs targeting IL-5 and IL-4Rα, 
i.e. targeting simultaneously IL-4, IL-13 and IL-5 signaling pathways, has not been performed in patients 
and could be very costly and impractical to set up, given that the established Abs have their own dosing 
interval. Therefore, we set out to study the feasibility of developing one single therapeutic molecule, a 
bispecific Ab, that targets simultaneously IL-4Rα and IL-5.  
We exploited a llama-based Ab platform to generate neutralizing IL-4Rα and IL-5 monospecific 
conventional Abs. After confirmation of their purity and functionality, we showed a synergistic effect 
of these two monospecific Abs injected in combination during challenge of HDM-exposed mice. 
Whereas the individual Abs each targeted certain aspects of the disease, only the combination of both 
monotherapies synergistically inhibited GCM and BHR when given during the allergen challenge phase. 
This finding was unexpected since none of the monotherapies reduced BHR (Fig 1). Prompted by these 
data, we sought to generate one single therapeutic molecule, an anti-IL-4Rα/IL-5 bispecific Ab. The 
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bispecific Ab, containing the HCs and the LCs of the parental monoclonal Abs, was isolated using a 
dual anti-idiotypic purification process.26 Notably, the bispecific Ab maintained the binding capacities 
of its parental molecules and was therefore tested in the same murine HDM model of asthma. 
Interestingly, the bispecific Ab reduced eosinophilic lung inflammation and prevented GCM in response 
to HDM challenge, confirming the results obtained with the combination of both monospecific Abs and 
showing the feasibility to generate a bispecific Ab with enhanced potential for asthma treatment in this 
preclinical model. Indeed, the combination of both monotherapies as well as the bispecific Ab reduced 
the mRNA expression levels of Muc5ac and Agr2 (coding for goblet cell proteins that are associated 
with increased mucus production), and of Spdef (coding for a transcription factor that promotes GCM) 
(Fig 2, D).37 More remarkably, treatment with either the combination of both monotherapies or the 
bispecific Ab protected lungs equally well from HDM induced BHR, as assessed by methacholine 
induced bronchoconstriction (Fig 2, E). 
These data obtained in a relevant asthma model employing HDM allergen for sensitization and 
challenge are different from previous studies performed in the ovalbumin-driven mouse asthma model. 
It was indeed shown in ovalbumin-driven models that individual blockade of IL-4Ra or even only IL-
13 was sufficient to block GCM and BHR.35, 49 We speculate that these different outcomes are caused 
by the fact that in the ovalbumin-driven model of asthma, the allergen challenge strictly depends on the 
adaptive TH2 immune response triggered by harmless ovalbumin proteins, whereas in the HDM model, 
the allergen challenge phase results from an innate and adaptive immune response to HDM that contains 
many proteases and danger associated pathogen-associated molecular patterns that can elicit responses 
from epithelial cells and many innate immune cells like ILC2s, basophils, mast cells and eosinophils 
simultaneously.2 To block GCM and BHR in this setting, we speculate that it is important to suppress 
several cytokines simultaneously. Even in the OVA model, it was previously demonstrated that BHR 
and tissue eosinophilia were intact in ovalbumin-sensitized and -challenged Il-4ra-/- mice, yet fully 
abolished when these mice were additionally rendered genetically deficient in Il5.50 Mechanistically, the 
potential of T cells to produce IL-13 is strongly enhanced by the presence of eosinophils that depend on 
IL-5.51, 52 It was also recently shown in mice that eosinophils act in concert with IL-13 from T cells to 
induce GCM, through release of eosinophil peroxidase.53 It is also possible that eosinophils produce 
cytokines like TGF-β or other granule contained mediators that could contribute to GCM. Although 
these studies showed cooperation between IL-5/eosinophils and the IL-4/IL-13 axis, they were 
performed in constitutive gene deficient mice, suggesting that the effects might have been caused by 
alterations of the sensitization process. We show here however, that using therapeutic Abs in already 
sensitized mice, we can induce a synergism that should lead to better therapy. 
In summary, we identified a novel neutralizing IL-4Rα/IL-5 bispecific Ab, which by means of 
a synergistic mechanism effectively reduced eosinophilic lung inflammation, prevented GCM and 
inhibited BHR in response to HDM challenge. The results of our preclinical study may lead to clinical 
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trials with a similar human IL-4Rα/IL-5 bispecific Ab approach in patients with moderate-to-severe 
asthma or with other chronic airway disorders in which mucus overproduction is often seen. 
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FIG 1. Combination of anti-IL-4Rα and anti-IL-5 monospecific Abs injected during challenge in 
a murine HDM model of asthma inhibited GCM and BHR. A, Experimental setup of HDM-exposed 
C57BL/6J mice treated with Abs during challenge. B, Differential cell counts in BAL fluid of HDM-
exposed mice that received the anti-IL-4Rα monospecific Ab, anti-IL-5 monospecific Ab, combination 
of monospecific Abs or an irrelevant IgG2a Ab analysed by FACS. C, Cytokine (IL-5 and IL-13) 
production by MLN cells restimulated with HDMs for three days ex vivo determined by ELISA. D, 
Serum levels of HDM-specific IgE and IgG1 determined by ELISA. E, Muc5AC confocal staining in 
mouse lungs after Ab treatments. F, Lung mRNA expression levels of Muc5ac, Spdef and Agr2 
determined by qRT-PCR. G, BHR measured after exposure to increasing doses of methacholine using 
Flexivent (SCIREQ). Data are representative of three independent experiments, with at least n = 6 mice 
per group and are means ± SEMs. ns: not significant, *P≤0.05, **P≤0.01, ***P≤0.001 and 
****P≤0.0001 versus HDM-sensitized and -challenged mice treated with an irrelevant IgG2a Ab. 
 
FIG 2. Anti-IL-4Rα/IL-5 bispecific Ab injected during challenge in a murine HDM model of 
asthma inhibited GCM and BHR. A, Differential cell counts in BAL fluid of HDM-exposed mice 
treated with the anti-IL-4Rα monospecific Ab, anti-IL-5 monospecific Ab, combination of monospecific 
Abs, anti-IL-4Rα/IL-5 bispecific Ab or an irrelevant IgG2a Ab analysed by FACS. B, Cytokine (IL-5 
and IL-13) production by MLN cells restimulated with HDMs for three days ex vivo determined by 
ELISA. C, Serum levels of HDM-specific IgE and IgG1 determined by ELISA. D, Lung mRNA 
expression levels of Muc5ac, Spdef and Agr2 determined by qRT-PCR. E, BHR measured after exposure 
to increasing doses of methacholine using Flexivent (SCIREQ). Data are representative of two 
independent experiments, with n = 6 mice per group and are means ± SEMs. ns: not significant, *P≤0.05, 
**P≤0.01, ***P≤0.001 and ****P≤0.0001 versus HDM-sensitized and -challenged mice treated with 
an irrelevant IgG2a Ab. 
 
FIG E1. Anti-IL-4Rα and anti-IL-5 monospecific Abs generated using a llama-based Ab platform 
and characterized in vitro. A, Two llamas (Lama glama) were immunized with six weekly injections 
of mouse IL-4Rα-Fc and mouse IL-5. After immunization, total RNA was extracted from peripheral 
blood lymphocytes, and the cDNAs encoding the VL-CL and VH-CH1 domains were PCR-amplified. 
Amplicons were cloned into the phagemid vector pCB3 leading to the expression of Fab fragments fused 
to phage pIII coat protein. Recombinant phages were selected on immobilized target proteins during 
three rounds of panning resulting in the enrichment of phages displaying IL-5 or IL-4Rα-specific Fabs. 
The cDNAs encoding the VH and VL domains of selected Fab fragments were engineered into two 
separate mammalian expression vectors containing the cDNAs encoding the CH1, hinge, CH2 and CH3 
domains of a mouse IgG2a-N297A Ab, or the CL, respectively. B, Confirmation of the purity and 
homogeneity of the anti-IL-4Rα and anti-IL-5 Abs analysed by SDS-PAGE under non-reducing and 
reducing conditions. C, Representative SPR sensorgram of the interactions between the anti-IL-4Rα 
monospecific Ab (or irrelevant IgG2a Ab) at varying concentrations (0-20 µg/mL) and the immobilized 
target IL-4Rα-Fc. D, Representative SPR sensorgram of the interactions between the anti-IL-5 
monospecific Ab (or irrelevant IgG2a Ab) at varying concentrations (0-20 µg/mL) and the immobilized 
target IL-5. E, Representative SPR sensorgrams of the interactions between a mixture composed of a 
monospecific Ab (IL-4Rα, IL-5 or irrelevant IgG2a Ab) and its target (IL-4Rα or IL-5), and the 
immobilized proteins (IL-4, IL-13Rα or IL-5Rα). F, Anti-IL-4Rα (square) and anti-IL-5 (triangle) 
monospecific Abs potently inhibited mouse IL-4- and IL-5-induced HT-2 and TF-1 cell proliferation, 
respectively. Results are expressed as mean of triplicates ± SEM of two independent experiments. 
G, Anti-IL-4Rα monospecific Ab (blue) potently inhibited IL-4 induced MHC class II antigen 
expression on B cells as analyzed by FACS. PlacZ: E. coli lac Z promoter; RBS: ribosome binding site; 
S: signal peptide; H: poly-histidine; T: MYC-tag; AMBER: amber stop codon; gIII: phage gene 
encoding the coat pIII protein. 
 
FIG E2. Anti-IL-4Rα/IL-5 bispecific Ab purified using a dual anti-idiotypic purification process 
maintained the binding capacities of the parental molecules. A, Schematic representation of the dual 
anti-idiotypic purification process to isolate a desired and properly paired bispecific Ab (framed) 
containing the knobs-into-holes mutations, which create a symmetric-to-asymmetric complementarity 
design. (a) From a mixture of four possible combinations formed by alternative LCs pairings, an anti-
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idiotypic VHH recognizing only the correct HC/LC pairing of the anti-IL-4Rα monospecific Ab is used 
to extract the two molecules containing this pairing (b). Then, a second anti-idiotypic column (VHH 
anti-IL-5 monospecific Ab) is used to only collect the bispecific Ab containing the properly paired 
HC/LC of the anti-IL-5 monospecific Ab. (c) This leads to the isolation of the desired anti-IL-4Rα/IL-5 
bispecific Ab with correct HC/LC pairings. B, Confirmation of the purity and homogeneity of the 
bispecific Ab analysed by high-resolution mass spectrometry. The bispecific Ab had a molecular mass 
(143.9 kDa) intermediate to the parental anti-IL-4Rα (144.6 kDa) and anti-IL-5 (143.5 kDa) 
monospecific Abs. C, SPR signals measured after subsequent injection of the anti-IL-4Rα monospecific 
Ab, anti-IL-5 monospecific Ab or anti-IL-4Rα/IL-5 bispecific Ab, and IL-4Rα-Fc or IL-5, on coated IL-
4Rα-Fc. D, SPR signals measured after subsequent injection of the anti-IL-4Rα monospecific Ab, anti-
IL-5 monospecific Ab or anti-IL-4Rα/IL-5 bispecific Ab, and IL-4Rα-Fc or IL-5, on coated IL-5. 
 
FIG E3. Combination of anti-IL-4Rα and anti-IL-5 monospecific Abs injected during sensitization 
and challenge in a murine HDM model of asthma reduced lymphocytosis and eosinophilia. A, 
Experimental setup of HDM-exposed C57BL/6J mice with Ab treatment during sensitization and 
challenge. B, Differential cell counts in BAL fluid of mice that received the anti-IL-4Rα monospecific 
Ab, anti-IL-5 monospecific Ab, combination of monospecific Abs or an irrelevant IgG2a Ab analysed 
by FACS. Data are representative of two independent experiments, with n = 6 mice per group and are 
means ± SEMs. ns: not significant, *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001 versus HDM-
sensitized and -challenged mice treated with an irrelevant IgG2a Ab. 
 
 






